One of the research goals highlighted in the Action Plan for Liver Disease of the National Institutes of Health is to develop means, including anti-viral antibodies, to prevent recurrence of hepatitis C virus (HCV) after liver transplantation. HCV associated liver failure is the most common indication for liver transplantation but recurren HCV invariably occurs after transplantation and can lead to rapid graft loss. The immunosuppressed liver transplant recipients tolerate the side effects of IFN-? and ribavirin poorly and therefore new strategies for prevention and/or treatment of HCV in the transplant setting are urgently required. The long-term objective of this application is to develop an effective and tolerable antibody cocktail to prevent recurrent HCV, and the same treatment may also be useful in preventing infection in the cases of accidental virus exposure of healthcare/laboratory workers, or in high risk populations.
The specific aims are (i) to generate human monoclonal antibodies (mAbs) to diverse conserved neutralizing viral epitopes of HCV by phage-display antibody technology;(ii) to generate highly potent HCV neutralizing antibodies by function screen;(iii) to understand the mechanisms of virus neutralization by the antibodies;(iv) to evaluate the efficacy of the mAbs in protecting a recently developed genetically humanized mouse model for HCV study upon challenges by multiple heterologous HCV genotypes. A demonstration of significant protection by the antibody or antibody cocktail would provide the scientific foundation for further investigation of this passive antibody approach in th prevention of recurrent HCV in clinical settings.
Hepatitis C virus (HCV)-associated liver failure is the most common indication for liver transplantation. An effective and tolerable means to prevent re-infection after liver transplant for HCV is urgently needed. The goal of this proposal is to discover a cocktail of highly potent human monoclonal antibodies to prevent recurrent HCV and to understand the molecular mechanisms of their neutralizing activities.
|von Schaewen, Markus; Ploss, Alexander (2014) Murine models of hepatitis C: what can we look forward to? Antiviral Res 104:15-22|
|Ruwona, Tinashe B; Giang, Erick; Nieusma, Travis et al. (2014) Fine mapping of murine antibody responses to immunization with a novel soluble form of hepatitis C virus envelope glycoprotein complex. J Virol 88:10459-71|
|Ding, Qiang; von Schaewen, Markus; Ploss, Alexander (2014) The impact of hepatitis C virus entry on viral tropism. Cell Host Microbe 16:562-8|
|Carlsen, Thomas H R; Pedersen, Jannie; Prentoe, Jannick C et al. (2014) Breadth of neutralization and synergy of clinically relevant human monoclonal antibodies against HCV genotypes 1a, 1b, 2a, 2b, 2c, and 3a. Hepatology 60:1551-62|
|Mathiesen, Christian K; Jensen, Tanja B; Prentoe, Jannick et al. (2014) Production and characterization of high-titer serum-free cell culture grown hepatitis C virus particles of genotype 1-6. Virology 458-459:190-208|
|Ruwona, Tinashe B; Mcbride, Ryan; Chappel, Rebecca et al. (2014) Optimization of peptide arrays for studying antibodies to hepatitis C virus continuous epitopes. J Immunol Methods 402:35-42|
|de Jong, Ype P; Dorner, Marcus; Mommersteeg, Michiel C et al. (2014) Broadly neutralizing antibodies abrogate established hepatitis C virus infection. Sci Transl Med 6:254ra129|
|von Schaewen, Markus; Ding, Qiang; Ploss, Alexander (2014) Visualizing hepatitis C virus infection in humanized mice. J Immunol Methods 410:50-9|
|Kong, Leopold; Giang, Erick; Nieusma, Travis et al. (2013) Hepatitis C virus E2 envelope glycoprotein core structure. Science 342:1090-4|
|Dorner, Marcus; Horwitz, Joshua A; Donovan, Bridget M et al. (2013) Completion of the entire hepatitis C virus life cycle in genetically humanized mice. Nature 501:237-41|
Showing the most recent 10 out of 14 publications